Friday, 13 November 2026European Markets

YARA INTERNATIONAL, APERAM, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(VIANEWS) - YARA INTERNATIONAL (YAR.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Basic Materials sector.

Financial Asset Price Forward Dividend Yield Return on Equity
YARA INTERNATIONAL (YAR.OL) kr407.70 14.41% 13.08%
APERAM (APAM.AS) €27.76 7.33% 8.75%
ALTRI SGPS (ALTR.LS) €4.31 5.45% 24.52%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. YARA INTERNATIONAL (YAR.OL)

14.41% Forward Dividend Yield and 13.08% Return On Equity

Yara International ASA provides crop nutrition and industrial solutions in Norway, European Union, Europe, Africa, Asia, North and Latin America, Australia, and New Zealand. The company offers ammonium- and urea-based fertilizers; compound fertilizers that contain plant nutrients, such as nitrogen, phosphorus, and potassium; coatings; biostimulants; organic-based fertilizers; green fertilizers are nitrate-based mineral fertilizers, as well as foliar and fertigation solutions; and nitrate, calcium nitrate, micronutrient, and fertigation fertilizers. It also offers digital solutions, such as variable rate application solutions; N-Sensor, a tractor-mounted hardware; N-Tester, a hand held nitrogen measurement tool; and Atfarm, a digital toolbox for farmer. The company sells its products under YaraBela, YaraMila, YaraLiva, YaraVita, YaraRega, YaraTera, YaraSuna, and YaraVera and brands. Yara International ASA was founded in 1905 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, YARA INTERNATIONAL has a trailing twelve months EPS of kr41.38.

PE Ratio

YARA INTERNATIONAL has a trailing twelve months price to earnings ratio of 9.85. Meaning, the purchaser of the share is investing kr9.85 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.08%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is a negative 38.6% and a negative 62%, respectively.

More news about YARA INTERNATIONAL.

2. APERAM (APAM.AS)

7.33% Forward Dividend Yield and 8.75% Return On Equity

Aperam S.A., together with its subsidiaries, engages in the production and sale of stainless and specialty steel products worldwide. It operates through four segments: Stainless & Electrical Steel; Services & Solutions; Alloys & Specialties; and Recycling & Renewables. The company offers range of stainless steel products, including grain oriented and non-grain oriented electrical steel products, and specialty alloys. It is also involved in the distribution of its products; and the provision of transformation services that include value added and customized steel solutions. In addition, the company designs, produces, and transforms various specialty alloys and other specific stainless steels in forms, such as bars, semis, cold-rolled strips, wire and wire rods, and plates in a range on grades. Further, it engages in the trading, processing, and recycling of raw materials, such as superalloys and titanium; provides Recyco, an electric arc furnace recycling facility that retrieves dust and sludge to recycle stainless steel raw materials and reduce waste; and produces wood and charcoal from cultivated eucalyptus forests. The company serves customers in aerospace, automotive, catering, construction, household appliances, electrical engineering, industrial processes, medical, and oil and gas industries. It distributes its products through a network of steel service centers, transformation facilities, and sales offices. The company was incorporated in 2010 and is headquartered in Luxembourg City, Luxembourg.

Earnings Per Share

As for profitability, APERAM has a trailing twelve months EPS of €4.15.

PE Ratio

APERAM has a trailing twelve months price to earnings ratio of 6.69. Meaning, the purchaser of the share is investing €6.69 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.75%.

Sales Growth

APERAM's sales growth is negative 14.1% for the current quarter and negative 0.6% for the next.

More news about APERAM.

3. ALTRI SGPS (ALTR.LS)

5.45% Forward Dividend Yield and 24.52% Return On Equity

Altri, SGPS, S.A. produces and sells cellulosic fibers and energy in Portugal and internationally. The company produces pulp products for various application including production of paper, tissue, and printing and writing papers; and dissolving pulp for use of textile production. It is also involved timber commercialization; forest management; production of forest-based renewable energy, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. The company was incorporated in 2005 and is headquartered in Porto, Portugal.

Earnings Per Share

As for profitability, ALTRI SGPS has a trailing twelve months EPS of €0.74.

PE Ratio

ALTRI SGPS has a trailing twelve months price to earnings ratio of 5.83. Meaning, the purchaser of the share is investing €5.83 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.52%.

Moving Average

ALTRI SGPS's worth is under its 50-day moving average of €4.31 and below its 200-day moving average of €4.55.

More news about ALTRI SGPS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com